Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLESTID vs FLAVORED COLESTID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.
Adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Digoxin toxicity (off-label),Hyperthyroidism (off-label),Pseudomembranous colitis (off-label)
Adjunctive therapy for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (Fredrickson Type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Off-label: Digoxin toxicity, pseudomembranous colitis, methotrexate toxicity
5-10 g orally once or twice daily, maximum 30 g/day.
5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Not applicable due to non-absorbable resin; systemic absorption is negligible. Terminal half-life not defined.
Not absorbed systemically; not metabolized; excreted unchanged in feces.
Colestipol is not absorbed systemically; it acts locally in the gastrointestinal tract and is excreted unchanged in feces.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Primarily fecal as insoluble complex (90-95%); <5% renal as glucuronide conjugate; minimal biliary elimination.
Not significantly absorbed; binding not applicable
Does not bind to plasma proteins as it is not absorbed.
Not applicable (non-absorbed; confined to gastrointestinal lumen)
Not applicable; minimal systemic absorption (Vd essentially 0).
Oral: <0.05% (negligible systemic absorption)
Oral bioavailability is <0.05% via absorption; acts locally in GI tract.
No specific dosage adjustment required for renal impairment; use with caution in patients with renal dysfunction due to potential for hyperchloremic metabolic acidosis.
No specific recommendations; use caution in severe renal impairment due to potential accumulation of inactive ingredients. GFR <30 m L/min: consider alternative agents or reduced dose under clinical monitoring.
No specific dosage adjustment required for hepatic impairment; use with caution in patients with pre-existing gastrointestinal disorders.
No specific guidelines for Child-Pugh scores; no expected alterations in pharmacokinetics as drug is not systemically absorbed. Use with caution in severe hepatic impairment due to potential electrolyte disturbances.
Safety and efficacy not established; limited data suggest 5-10 g daily in divided doses for children aged 12-18 years.
Not established for children under 18 years; safety and efficacy not determined. In adolescents (≥18 years) use adult dosing titrated to effect with close monitoring.
No specific dosage adjustment; monitor for constipation and gastrointestinal adverse effects; initiate at low end of dosing range.
Start at low end of dosing range (5 grams once daily); titrate slowly. Monitor for constipation, electrolyte imbalances, and drug interactions. No specific age-based dose adjustments recommended.
No FDA black box warning.
Not applicable (no FDA black box warning).
May cause fecal impaction, especially in patients with hemorrhoids or constipation.,May interfere with absorption of fat-soluble vitamins (A, D, E, K).,May reduce absorption of other drugs; take other medications at least 1 hour before or 4-6 hours after colestipol.,Use with caution in patients with bleeding tendencies or with impaired hepatic function.,Hypertriglyceridemia may occur.
Can cause hypertriglyceridemia; caution in patients with pre-existing hypertriglyceridemia. Risk of fat-soluble vitamin deficiency (A, D, E, K) with long-term use. May interfere with absorption of other medications; administer other drugs at least 1 hour before or 4 hours after colestipol. Constipation may worsen hemorrhoids. Use caution in patients with gastrointestinal motility disorders or history of bowel obstruction.
Complete biliary obstruction,Hypersensitivity to colestipol or any component of the formulation
Complete biliary obstruction (contraindicated because ineffective). Hypersensitivity to colestipol or any component of the formulation.
Colestipol may bind to fat-soluble vitamins (A, D, E, K) and decrease their absorption. Take vitamin supplements at least 1 hour before or 4 hours after colestipol. High-fat meals may reduce binding efficacy; take with meals containing moderate fat.
Take with meals to enhance efficacy. Avoid high-fat meals as they reduce binding capacity. Mix with non-carbonated beverages or soft foods; do not take dry. Can be mixed with orange juice without affecting efficacy. May reduce absorption of fat-soluble vitamins; consider vitamin supplementation if long-term therapy.
FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefore, fetal risk is considered minimal. Trimester-specific risks: First trimester: No known risk due to lack of absorption. Second and third trimesters: Potential for decreased absorption of fat-soluble vitamins and folate, which may affect fetal development. Vitamin K deficiency may increase neonatal bleeding risk.
Colestid (colestipol) is not systemically absorbed; therefore, no fetal exposure is expected. No teratogenic effects have been reported in animal studies or human data. However, use during pregnancy may impair absorption of fat-soluble vitamins (A, D, E, K), potentially affecting fetal development. Trimester-specific risks: First trimester: theoretical risk of vitamin deficiency. Second and third trimesters: risk of vitamin K deficiency leading to neonatal hemorrhage. Overall, the drug is considered low risk due to lack of systemic absorption.
Colestipol is not absorbed systemically, thus is not expected to be excreted into breast milk. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for potential gastrointestinal effects secondary to maternal use.
Colestid is not absorbed systemically, so it is unlikely to be excreted into breast milk. No data on M/P ratio. It is considered compatible with breastfeeding, but caution is advised due to potential interference with maternal absorption of fat-soluble vitamins, which could affect milk composition. Monitor infant for signs of vitamin deficiency.
No dose adjustment required due to lack of systemic absorption. However, ensure adequate nutritional status: monitor fat-soluble vitamin supplementation (A, D, E, K) and folate; increase interval between colestipol and prenatal vitamins/food to 1 hour before or 4 hours after.
No dose adjustment is required due to lack of systemic absorption. However, ensure adequate supplementation of fat-soluble vitamins (A, D, E, K) and folic acid, as colestipol may reduce their absorption. Administer colestipol and vitamin supplements at least 4–6 hours apart to minimize interaction.
Colestipol is a bile acid sequestrant; administer with meals to bind bile acids. Monitor for constipation and increase fluid/fiber intake. Reduce doses of other medications by at least 1 hour before or 4 hours after colestipol. May increase triglyceride levels; monitor lipids. Use with caution in patients with renal impairment.
Flavored Colestid (colestipol) is a bile acid sequestrant used as adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol. Administer with meals to maximize binding of bile acids. Mix with liquids (water, juice, milk) or soft foods (applesauce, crushed pineapple). Avoid concurrent administration with other medications; give at least 1 hour before or 4 hours after other oral drugs to reduce interference with absorption. Monitor for constipation, which can be severe; increase fluid intake. May reduce absorption of fat-soluble vitamins (A, D, E, K); consider supplementation in long-term therapy.
Take exactly as prescribed, usually once or twice daily with food and a full glass of water.,Do not take other medications within 1 hour before or 4 hours after colestipol.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Inform your doctor if you have a history of hemorrhoids or digestive problems.,Keep out of reach of children; store at room temperature.
Take this medication with meals and plenty of water to prevent constipation.,Mix the powder with at least 3-6 ounces of liquid (water, juice, milk) or soft food (applesauce, crushed pineapple) and drink immediately.,Do not take other medications at the same time; take them at least 1 hour before or 4 hours after colestipol.,Common side effects include constipation, bloating, and gas; increase fiber and fluid intake to help.,Contact your doctor if you have severe stomach pain, rectal bleeding, or signs of vitamin deficiency (unusual bruising, bone pain).,Continued adherence to cholesterol-lowering diet and exercise is essential.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLESTID vs FLAVORED COLESTID, answered by our medical review team.
COLESTID is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.. FLAVORED COLESTID is a Bile Acid Sequestrant that works by Colestid (colestipol) is a bile acid sequestrant. It binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased hepatic conversion of cholesterol to bile acids, thereby lowering serum low-density lipoprotein (LDL) cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLESTID and FLAVORED COLESTID depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLESTID is: 5-10 g orally once or twice daily, maximum 30 g/day.. The standard adult dose of FLAVORED COLESTID is: 5-30 grams orally daily, divided into 2-4 doses, starting at 5 grams once daily and increasing by 5 grams every 4-7 days as tolerated; taken with meals and mixed with at least 4-8 oz of liquid per dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLESTID and FLAVORED COLESTID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLESTID is classified as Category C. FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefor. FLAVORED COLESTID is classified as Category C. Colestid (colestipol) is not systemically absorbed; therefore, no fetal exposure is expected. No teratogenic effects have been reported in animal studies or human data. However, us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.